詹勝傑副主任

詹勝傑醫師 
醫師代號 : 47022

學       歷 :  慈濟大學醫學系畢業

專 長

  • 一般核醫影像檢查
  • ㄧ般正子影像檢查
  • 正子暨磁共振影像檢查
  • 核素治療

現 職

  • 佛教慈濟醫療財團法人花蓮慈濟醫院核子醫學科副主任
  • 教育部部定副教授
  • 中華民國核醫學會理事

經 歷

  • 林口長庚醫院核醫科 住院醫師  
  • 林口長庚醫院核醫科 主治醫師
  • 嘉義長庚醫院核醫科 科主任
  • 基隆長庚醫院核醫科 科主任
  • 林口長庚醫院核醫科 科主任

專科證書

  • 核子醫學科專科醫師證書

專科學會

  • 中華民國核醫學學會

期刊論文

  1. Diagnosis of Bile Peritonitis Caused by Rupture of Choledochal Cyst via 99mTc-DISIDA Cholescintigraphy: A Case Report. Ann Nucl Med Sci 2002;15:147-151. (First author)
  2. Diffuse cutaneous plasmacytomas demonstrated on gallium-67 imaging. Kaohsiung J Med Sci. 2003;19(4):193-5.
  3. False positive fluorine-18 fluorodeoxy-D-glucose positron emission tomography finding caused by osteoradionecrosis in a nasopharyngeal carcinoma patient. Br J Radiol. 2004 ;77:257-260. DOI: http://dx.doi.org/10.1259/bjr/69516821 (SCI A)
  4. Nodal metastases of nasopharyngeal carcinoma: patterns of disease on MRI and FDG PET. Eur J Nucl Med Mol Imaging. 2004;31:1073-1080. DOI:10.1007/S00259-004-9 (SCI A)
  5. Clinical usefulness of 18F-FDG PET in nasopharyngeal carcinoma patients with questionable MRI findings for recurrence. J Nucl Med. 2004;45:1669-1676. (SCI A)
  6. False-Positive Findings on F-18 Fluoro-2-deoxy-D-glucose Positron Emission Tomography in a Patient With Nasopharyngeal Carcinoma and Extensive Sinusitis. Clin Nucl Med. 2005;30:62–63. DOI:10.1200/JCO.2010.28.7052. (First author) (SCI A)
  7. Are dual-phase (18)F-FDG PET scans necessary in nasopharyngeal carcinoma to assess the primary tumour and loco-regional nodes? Eur J Nucl Med Mol Imaging. 2005;32:541-548.DOI:10.1007/S00259-004-1719-2. (SCI A)
  8. Clinical Impact of 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients with Lung Cancer: Experience of Linko Chang-Gung Memorial Hospital. Ann Nucl Med Sci. 2005;18:67-77. (First author)
  9. 18F-FDG PET and CT/MRI in Oral Cavity Squamous Cell Carcinoma: A Prospective Study of 124 Patients with Histologic Correlation. J Nucl Med. 2005;46:1136-1143. (SCI A)
  10. Nasopharyngeal carcinoma staging by (18)F-fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2005;62:501-507. DOI: 10.1016/j.ijrobp.2004.09.057. (SCI A)
  11. The value of 18F-FDG PET in the detection of stage M0 carcinoma of the nasopharynx. J Nucl Med. 2005;46:405-410. (SCI A)
  12. Staging of untreated squamous cell carcinoma of buccal mucosa with 18F-FDG PET: comparison with head and neck CT/MRI and histopathology. J Nucl Med. 2005; 46:775-781. (SCI A)
  13. [18F]fluorodeoxyglucose positron emission tomography is more sensitive than skeletal scintigraphy for detecting bone metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol. 2006; 24:599-604. DOI:10.1200/JCO.2005.03.8760 (SCI A)
  14. Upper pole of a duplex kidney mimicking adrenal incidentaloma in 18F-fluoro-2-deoxy-D-glucose positron emission tomography: a pitfall in diagnosis. Br J Radiol. 2006; 79:50-52. DOI: http://dx.doi.org/10.1259/bjr/38262574. (First author) (SCI A)
  15. (18)F-FDG-PET for evaluation of the response to concurrent chemoradiation therapy with intensity-modulated radiation technique for Stage T4 nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006; 65:1307-1314. DOI: 10.1016/j.ijrobp.2006.02.031. (SCI A)
  16. Advantages and pitfalls of 18F-fluoro-2-deoxy-D-glucose Positron Emission Tomography in detecting locally residual or recurrent nasopharyngeal carcinoma: comparison with Magnetic Resonance Imaging. Eur J Nucl Med Mol Imaging. 2006;33:1032-1040.DOI:10.1007/s00259-005-0054-6. (First author) (SCI A)
  17. Differential Roles of 18F-FDG PET in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma after Primary Curative Therapy: Response Evaluation and Impact on Management. J Nucl Med. 2006; 47:1447-1454. (First author) (SCI A)
  18. Prospective Study of [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography and Magnetic Resonance Imaging in Oral Cavity Squamous Cell Carcinoma With Palpably Negative Neck. J Clin Oncol. 2006;24:4371-4376. DOI:10.1200/JCO.2006.05.7349. (SCI A)
  19. 18F-FDG PET can replace conventional work-up in primary M staging of nonkeratinizing nasopharyngeal carcinoma. J Nucl Med. 2007;48:1614-1619. DOI:10.2967/jnumed.107.043406. (SCI A)
  20. Intractable bleeding from solitary mandibular metastasis of hepatocellular carcinoma. World J Gastroenterol. 2007;13:4526-4528. (SCI A)
  21. Prediction for distant failure in patients with stage M0 nasopharyngeal carcinoma: The role of standardized uptake value. Oral Oncol. 2009;45:52-8. DOI:10.1016/j.oraloncology.2008.03.010. (First author) (SCI A)
  22. Distant metastases and synchronous second primary tumors in patients with newly diagnosed oropharyngeal and hypopharyngeal carcinomas: evaluation of (18)F-FDG PET and extended-field multi-detector row CT. Neuroradiology. 2008;50:969-79 DOI:10.1007/s00234-008-0426-2. (SCI A)
  23. Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up. Eur J Nucl Med Mol Imaging. 2009 ;36(1):12-22. DOI:10.1007/s00259-008-0918-7. (SCI A)
  24. Salvage surgery after failed chemoradiotherapy in squamous cell carcinoma of the esophagus. Eur J Surg Oncol. 2009;35(3):289-294. DOI:10.1016/j.ejso.2008.02.014. (SCI A)
  25. Red blood cell scintigraphy in children with acute massive gastrointestinal bleeding. Pediatrics International 2008; 50:199-203. DOI:10.1111/j.1442-200X.2008.02552.x.
  26. Pretreatment T3-4 Stage is an Adverse Prognostic Factor in Patients with Esophageal Squamous Cell Carcinoma Who Achieve Pathological Complete Response Following Preoperative Chemoradiotherapy. Ann Surg. 2009;249:392-396. DOI: 10.1097/SLA.0b013e3181949e9f. (SCI A)
  27. 18F-FDG PET for retropharyngeal lymph node metastasis in oropharyngeal and hypopharyngeal cancers: impact on diagnosis and prediction analysis. Nucl Med Commun. 2010;31:260-265. DOI:10.1097/MNM.0b013e3283360133. (First author) (SCI A)
  28. Comprehensive imaging of residual/ recurrent nasopharyngeal carcinoma using whole-body MRI at 3 T compared with FDG-PET-CT. Eur Radiol. 2010;20:2229-2240. DOI:10.1007/s00330-010-1784-9. (SCI A)
  29. Pretreatment evaluation of distant-site status in patients with nasopharyngeal carcinoma: accuracy of whole-body MRI at 3-Tesla and FDG-PET-CT. Eur Radiol. 2009;19:2965-2976. DOI: 10.1007/s00330-009-1504-5. (SCI A)
  30. PET/CT and 3-T whole-body MRI in the detection of malignancy in treated oropharyngeal and hypopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2011;38:996-1008. DOI: 10.1007/s00259-011-1740-1. (SCI A)
  31. 18F-FDG PET/CT and 3.0 Tesla Whole-body MRI for the Detection of Distant Metastases and Second Primary Tumors in Patients with Untreated Oropharyngeal/Hypopharyngeal Carcinoma: A Comparative Study. Eur J Nucl Med Mol Imaging. 2011;38:1607-1619. DOI:10.1007/s00259-011-1824-y (First author) (SCI A)
  32. Comparison of PET/CT and MRI for the detection of bone marrow invasion in patients with squamous cell carcinoma of the oral cavity. Oral Oncol. 2011; 47:288-295. DOI:10.1016/j.oraloncology.2011.02.010 (SCI A)
  33. Clinical utility of 18F-FDG PET parameters in patients with advanced nasopharyngeal carcinoma: predictive role for different survival endpoints and impact on prognostic stratification. Nucl Med Commun. 2011;32:989-996. DOI:10.1097/MNM.0b013e3283495662. (First author) (SCI A)
  34. Prognostic Significance of 18F-FDG PET Parameters and Plasma Epstein-Barr Virus DNA Load in Patients with Nasopharyngeal Carcinoma. J Nucl Med. 2012;53:21-28. DOI: 10.2967/jnumed.111.090696. (SCI A)
  35. Uterine cervical melanoma presenting with rapid progression detected by PET/CT. Acta Radiologica. 2012;1:16. Doi:10.1258/arsr.2012.120026 (SCI A)
  36. Utility of 18F-fluoride PET/CT and 18F-FDG PET/CT in the Detection of Bony Metastases in Heightened-risk Head and Neck Cancer Patients. J Nucl Med. 2012;53:1730-1735. DOI:10.2967/jnumed.112.104893. (First author) (SCI A)
  37. The role of (18)F-FDG PET/CT metabolic tumour volume in predicting survival in patients with metastatic nasopharyngeal carcinoma. Oral Oncol. 2013;49:71-78. DOI:10.1016/j.oraloncology.2012.07.016. (First author) (SCI A)
  38. Pretreatment (18)F-FDG PET standardized uptake value of primary tumor and neck lymph nodes as a predictor of distant metastasis for patients with nasopharyngeal carcinoma. Oral Oncol. 2013;49:169-174. DOI:10.1016/j.oraloncology.2012.08.011. (SCI A)
  39. Misinterpretation of FDG-avid Pelvic Lymph Node Lesions as Distant Failure in a Patient with Recurrent Lung Cancer. Annals of Nuclear Medicine and Molecular Imaging. 2012;25:206-210.
  40. Plasma Epstein-Barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma. Head Neck. 2012;34:1064-1070. (SCI A)
  41. Prognostic implications of post-therapy 18F-FDG PET in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy. Ann Nucl Med. 2013;27:710-719. (First author) (SCI, 54/133, Radiology, Nuclear Medicine & Medical Imaging)
  42. Clinical scenario of EBV DNA follow-up in patients of treated localized nasopharyngeal carcinoma. Oral Oncol. 2013;49:620-625. DOI:10.1016/j.oraloncology.2013.02.006 (SCI A)
  43. Dynamic contrast-enhanced MR imaging predicts local control in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiotherapy. PLoS One. 2013:7;8(8):e72230. DOI:10.1371/journal.pone.0072230 (SCI A)
  44. Interval Between Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma: Does Delayed Surgery Impact Outcome? Ann Surg Oncol. 2013:20:4245–4251. DOI:10.1245/s10434-013-3139-7. (SCI A)
  45. Detection of synchronous cancers by fluorodeoxyglucose positron emission tomography/computed tomography during primary staging workup for esophageal squamous cell carcinoma in Taiwan. PLoS One. 2013;8(11):e82812. eCollection 2013. DOI: 10.1371/journal.pone.0082812. (SCI A)
  46. Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma. World J Surg Oncol. 2014;12:170. DOI: 10.1186/1477-7819-12-170. (SCI A)
  47. Clinical utility of multimodality imaging with dynamic contrast-enhanced MRI, diffusion-weighted MRI, and 18F-FDG PET/CT for the prediction of neck control in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiation. PLoS One. 2014;9(12):e115933. (SCI A)
  48. F-18 FDG PET/CT as a Surveillance Tool for the Detection of Locoregionally Advanced Nasopharyngeal Carcinoma Recurrences in an Endemic Area. Annals of Nuclear Medicine and Molecular Imaging 2016;29:10-22 (First author)
  49. Pretreatment Dynamic Contrast-Enhanced MRI Improves Prediction of Early Distant Metastases in Patients With Nasopharyngeal Carcinoma. Medicine (Baltimore). 2016 Feb;95(6):e2567. doi: 10.1097/MD.0000000000002567. (SCI A)
  50. Dynamic contrast-enhanced MRI, diffusion-weighted MRI and 18F-FDG PET/CT for the prediction of survival in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiation. Eur Radiol. 2016 Nov;26(11):4162-4172. (SCI A) 
  51. Efficacy of vancomycin-releasing biodegradable poly(lactide-co-glycolide) antibiotics beads for treatment of experimental bone infection due to Staphylococcus aureus. J Orthop Surg Res. 2016; 11:52. (SCI A)
  52. Tumor heterogeneity measured on F-18 fluorodeoxyglucose positron emission  tomography/computed tomography combined with plasma Epstein-Barr Virus load predicts prognosis in patients with primary nasopharyngeal carcinoma. Laryngoscope. 2017;127:E22-E28. (First author) (SCI, 10/42, Otorhinolaryngology)
  53. Multiparametric imaging using 18F-FDG PET/CT heterogeneity parameters and functional MRI techniques: prognostic significance in patients with primary advanced oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiotherapy. Oncotarget. 2017 Mar 4;8(37):62606-62621. (First author)
  54. Higher body weight and distant metastasis are associated with higher radiation exposure to the household environment from patients with thyroid cancer after radioactive iodine therapy. Medicine (Baltimore). 2017 Sep;96(35):e7942. (SCI A)
  55. Correlation between overall survival and differential plasma and tissue tumor marker expression in nasopharyngeal carcinoma patients with different sites of organ metastasis. Oncotarget. 2016 Aug 16;7(33):53217-53229.
  56. Predictive value of 1H MR spectroscopy and 18F-FDG PET/CT for local control of advanced oropharyngeal and hypopharyngeal squamous cell carcinoma receiving chemoradiotherapy: a prospective study. Oncotarget. 2017 Dec 14;8(70):115513-115525.
  57. Clinical utility of simultaneous whole-body 18F-FDG PET/MRI as a single-step imaging modality in the staging of primary nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1297-1308. (First author) (SCI, 5/133, Radiology, Nuclear Medicine & Medical Imaging)
  58. Value of early evaluation of treatment response using 18F-FDG PET/CT parameters and the Epstein-Barr virus DNA load for prediction of outcome in patients with primary nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):650-660. (Corresponding author) (SCI, 5/133, Radiology, Nuclear Medicine & Medical Imaging)
  59. Combining the radiomic features and traditional parameters of 18F-FDG PET with clinical profiles to improve prognostic stratification in patients with esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and surgery. Ann Nucl Med. 2019 Sep;33(9):657-670. (Corresponding author) (SCI, 54/133, Radiology, Nuclear Medicine & Medical Imaging)
  60. Textural features on 18F-FDG PET/CT and dynamic contrast-enhanced MR imaging for predicting treatment response and survival of patients with hypopharyngeal carcinoma. Medicine (Baltimore). 2019 Aug;98(33):e16608. (Co-first author) (SCI, 89/165, Medicine, General & Internal).
  61. Comparison of 18F-FDG PET/MRI, MRI, and 18F-FDG PET/CT for the detection of synchronous cancers and distant metastases in patients with oropharyngeal and hypopharyngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2020;47(1):94-104. (Co-first author)(SCI, 5/133, Radiology, Nuclear Medicine & Medical Imaging)
  62. Radiation safety assessment of caregivers of thyroid cancer patients treated with 131I in Taiwan. Radiation Physics and Chemistry. 2020;172:108781. DOI: 10.1016/j.radphyschem.2020.108781.
  63. Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated With Definitive Chemoradiotherapy. Cancers (Basel) . 2020;12(3):607. doi: 10.3390/cancers12030607. (SCI A)
  64. Pretreatment 18F-FDG PET/CT texture parameters provide complementary information to Epstein-Barr virus DNA titers in patients with metastatic nasopharyngeal carcinoma. Oral Oncol. 2020;104:104628. doi:10.1016/j.oraloncology.2020.104628. (SCI A)
  65. Multiparametric PET/MRI in nasopharyngeal carcinoma: correlations between MRI functional parameters and 18F-FDG PET imaging biomarkers and their predictive value for treatment failure. Tzu Chi Med J. [Epub ahead of print] [cited 2020 Jun 3]. Available from: http://www.tcmjmed.com/preprintarticle.asp?id=282214 (First author)
  66. Preoperative F-18 fluorocholine PET/CT for the detection of hyperfunctioning parathyroid glands in patients with secondary or tertiary hyperparathyroidism: comparison with Tc-99m sestamibi scan and neck ultrasound. Ann Nucl Med. 2020 May 20. doi: 10.1007/s12149-020-01479-2. (Corresponding author) (SCI, 54/133, Radiology, Nuclear Medicine & Medical Imaging)
  67. Baseline circulating stem-like cells predict survival in patients with metastatic breast cancer. BMC Cancer. 2019 Dec 2;19(1):1167. (SCI A)

團隊陣容

Copyright © 2017 花蓮慈濟醫院. 版權所有. 地址:花蓮市中央路三段707號 連絡電話:03-8561825